Table 4 Comparison of cytogenetics of AML patients between our study and other studies worldwide
From: Cytogenetic profile of adult acute myeloid leukemia in Egypt: a single-center experience
Cytogenetic finding | Frequency (%) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Our study 2021 | Western population | Middle east population | Asian population | |||||||||
USA 2002 [34] | UK 2006 [33] | Spain 2006 [5] | Oman 2007 [27] | Tunisia 2012 [25] | KSA 2017 [11] | Morocco 2019 [12] | Morocco 2021 [13] | Japan 2008 [28] | China 2009 [31] | India 2020 [26] | ||
Normal karyotype | 56.7% | 48% | 45% | 36% | 38% | 37.1% | 36% | 42% | 44% | 41.8% | 42% | 34.7% |
Structural abnormalities: | ||||||||||||
t(8;21)(q22;q22) | 7.5% | 8.7% | 4% | 2.7% | 11% | 12.2% | 12% | 12.5% | 8.4% | 17.7% | 8% | 20.8% |
inv(16)/t(16;16)(p13;q22) | 7.5% | 7.9% | 2% | 2.7% | 3% | 3.8% | 7% | 3.3% | 4.7% | 4.1% | – | 21.3% |
t(v;11q23) | 7.5% | 4.5% | 2% | 3.3% | 2% | 3.5% | 6% | 1% | 1% | 5% | 1% | 3.4% |
t(15;17)(q24;q21) | 9.2% | – | 8% | 14.8% | 10% | 13.2% | 6% | 3.7% | 3.9% | – | 14% | 8.6% |
inv(3)/t(3;3)(q21;q26) | 1.6% | 1% | – | 3.2% | – | – | 2% | 0.6% | 0.2% | 0.8% | – | 3.4% |
t(9;22)(q34;q11) | 0.8% | – | 1% | – | – | – | – | – | 1.1% | 1.1% | 2% | – |
Complex karyotype | 0.8% | 2.5% | 15% | – | 8% | 10.8% | – | 7.4% | 12% | 6.4% | 6% | 2.3% |
Numerical abnormalities: | ||||||||||||
Trisomy 8 | 3.3% | 10.1% | 6% | 11.4% | 11% | 7% | 15% | 4.5% | 5.3% | – | 2% | – |
Trisomy 11 | 1.66% | 1.6% | 1% | 2.3% | – | – | – | – | 3.3% | – | – | – |
i(17)(q10) | 0.8% | – | – | – | – | – | – | – | – | – | – | – |
del(3q) | 0.8% | – | – | – | – | – | – | – | – | – | – | – |
Der(1)t(1;6)(p36;q22) | 0.8% | – | – | – | – | – | – | – | – | – | – | – |
-7/del(7q) | 0.8% | 7.8% | 5% | 8.6% | 5% | 3% | – | 2.9% | 2.7% | 0.3% | 1% | 1.1% |
del(5q) | – | 3.5% | 5% | 9.1% | 6% | 2.2% | – | 0.5% | – | 0.3% | 1% | 2.3% |